| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-12-13 | Biotie Therapies (Finland) National Institute on Drug Abuse (NIDA-USA) | nepicastat (SYN117) | cocaine dependence | clinical research | CNS diseases - Mental diseases | Clinical research agreement |
| 2011-12-13 | Prestwick Chemical (France) Pharma Plexus Holland (The Netherlands) | lead optimization services | collaboration |
Collaboration agreement | ||
| 2011-12-13 | Camurus (Sweden) Novartis (Switzerland) | octreotide product CAM2029 and the FluidCrystal® Injection depot technology | collaboration |
Licensing agreement | ||
| 2011-12-13 | Polytherics (UK) Nuron Biotech (USA) | PolyTherics’ TheraPEG™ conjugation technology | licensing |
Licensing agreement | ||
| 2011-12-13 | BiolineRx (Israel) Compugen (Israel) | Compugen-discovered drug candidates including the three peptides CGEN-855, CGEN-856 (now BL-7060) and CGEN-25017 (now BL-8010) | collaboration |
Inflammatory diseases - Cardiovascular diseases - Cancer - Oncology | Collaboration agreement | |
| 2011-12-09 | Dako (Denmark) Genentech a member of the Roche Group (USA-Switzerland) | HercepTest® and HER2 FISH pharmDx® as companion diagnostics for pertuzumab | advanced HER2-positive breast cancer | collaboration |
Cancer Oncology | Collaboration agreement |
| 2011-12-08 | Cellectis (France) Syngene International (India) | novel genetically customized cell lines for drug discovery studies | R&D |
R&D agreement | ||
| 2011-12-07 | The Roslin Institute of the University of Edinburgh (UK) - NewVectys (France) | new technologies for biomedical research | R&D |
R&D agreement | ||
| 2011-12-07 | MDxHealth (Belgium) University Hospital of Bonn (Germany) | PredictMDx™ | glioblastoma | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2011-12-07 | Protagen (Germany) Bayer HealthCare (Germany) | diagnostic biomarkers in endometriosis | endometriosis | R&D |
Gynecology - Women's health | R&D agreement |
| 2011-12-06 | Redbiotec (Switzerland) Intercell (Austria) | technology platform rePAX™ | undisclosed viral diseases | R&D |
Infectious diseases | R&D agreement |
| 2011-12-06 | Beactica (Sweden) Almac Discovery (UK) | Sprint™ | undisclosed | R&D |
undisclosed | R&D agreement |
| 2011-12-05 | HRA Pharma (France) Gedeon Richter (Hungary) | Esmya® (ulipristal acetate) | uterine fibroids (myoma) | distribution |
Gynecology - Women's health | Commercialisation agreement |
| 2011-12-05 | AstraZeneca (UK) Medical Research Council - MRC (UK) | Alzheimer’s disease, lung disease, motor neurone disease, muscular dystrophies | Neurodegenerative diseases - Cancer - Oncology - Lung diseases - Neuromuscular diseases - Rare diseases | R&D agreement | ||
| 2011-12-02 | MDX Health (Belgium) Celldex (USA) | epigenetic MGMT test, rindopepimut | glioblastoma multiforme | Cancer Oncology | Clinical research agreement | |
| 2011-12-02 | BMS (USA) Tibotec Pharmaceuticals-J&J (Ireland - USA) | daclatasvir (BMS-790052),TMC435 (The drug has been jointly developed by Medivir and Tibotec Pharmaceuticals) | patients with genotype 1 hepatitis C virus | Clinical collaboration |
Infectious diseases | Development agreement |
| 2011-12-01 | Boehringer Ingelheim (Germany) AVEO Pharmaceuticals (USA) | ficlatuzumab | non small cell lung cancer | development |
Cancer - Oncology | Development agreement |
| 2011-11-30 | VitamFero (France) Oniris (France) | new candidate vaccine against bovine neosporosis | bovine neosporosis | services |
Veterinary medicine | Services contract |
| 2011-11-30 | Q Chip (UK) undisclosed leading international speciality pharmaceutical company | sustained release depot of an undisclosed therapeutic peptide | development |
Development agreement | ||
| 2011-11-30 | Vitamfero (France) Oniris (France) | vaccine candidate against bovine (cattle) neosporosis | neosporosis | collaboration |
Veterinary medicine | Services contract |
